ALK and inflammatory myofibroblastic tumor: Preliminary data from the iMATRIX Alectinib phase I/II study (NCT04774718) in eight pediatric patients with ALK fusion-positive tumors (high-grade glioma (n = 3), IMT (n = 2), renal cell carcinoma (n = 2), and ALCL (n = 1)) showed responses in four patients (including one CR) and stable disease in two additional patients [61].